Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: BigDaddyMac who wrote (631)	6/15/1998 12:31:00 AM
From: Prospector	Read Replies (2) \| Respond to of 5402

Mr Vince Sir: One thing you might consider, That PHER-02 is a second generation drug pointed out many times in the past. The first generation has already been approved by the FDA, and tested on 15,000 humans with no side effects. Thank you Prospector

To: BigDaddyMac who wrote (631)	6/15/1998 8:47:00 AM
From: drdan	Respond to of 5402

Mitch, you are quite right that this will not happe overnight. However, that does not mean that tis company is not a resonable investment risk now or in the near future. Please remember that large pharmaceutical firms do not wait until Phase 3 human testing is done before they back a reserch company. all these companies need to see is a bit of data suggestive of success. Look at somatogen recently. Look at Alliance before J&J scaled back their financing. They got money for their product and they are not even close to being on the market. Folks you wont have a dead money stock, here. It will sink or swim in a short period of time -weeks to months, IMO. Mitch, your concern is appreciated but your comment is a bit exaggerated and perhaps not entirely relevant. BTW< are the deaths you refer to from the Jehovah's Witnesses testing? Have a good day.....